Humana (HUM, $28.4B mkt cap) is the fourth-largest Medicare Advantage carrier. The 10-Q filed Apr 29, 2026 was the first quarterly print since the Q4 2025 Star Ratings crisis drew the stock down 33% in a month into ≈$185. The print came in better than feared and the stock has since rallied to $236 (+36% in 30 days). Sell-side has caught the EPS magnitude. The cross-ticker pattern beneath it has not been synthesized.

What the filing says

Q1 2026 GAAP diluted EPS $9.83. Full-year guidance had been "at least $9." A single quarter equaled the floor — and management had explicitly framed Q1 as the worst quarter, since the BY2026 Star Ratings revenue headwind is uniform across quarters and Q1 carried the heaviest new-member benefit-ratio drag.

Insurance segment benefit ratio printed 89.4% (+200 bps YoY). The MD&A attributes the entire increase to mechanical effects — Star Ratings revenue loss (denominator) and new-member cohort mix — with the explicit characterization "largely stable benefits year over year." Insurance operating cost ratio improved 90 bps to 7.3%.

Individual MA membership 6.39M, +1.18M / +22.6% YoY — exceeded the ≈1M AEP guide. Buybacks resumed: $103M at $182 in February, first open-market repurchases since the crisis. $2.7B authorization remaining. MaxHealth (Florida primary care, $908M cash) closed Feb 13. RADV: HHS appealed the September 2025 N.D. Texas vacatur on Nov 21, 2025 — now "Humana v Kennedy" at the 5th Circuit. CenterWell segment income -26.3% on v28 final-year phase-in plus MaxHealth integration; revenue still grew 19.7%. No changes to risk factors.

What the market thinks

Forward P/E 15.54 implies sell-side consensus FY 2026 EPS near $15. Sell-side mean target $211 (lagged); April 30 cluster $246-270. Options ATM IV 42.8% (38th percentile), max pain $195. P/C OI 0.79 directionally bullish, but put IV is 8.1% above calls — atypical hedging beneath the rally. IV term structure peaks at Jun 18 (47.9%) and Nov 20 (53.5%) — the Q2 print and the post-AEP/STARS window are being priced.

Why the gap exists

Cross-ticker absorption not synthesized. UNH lost 965K MA seniors sequentially. ELV lost ≈355K (-15.8% YoY). HUM absorbed roughly 89% of the deliberate peer shed. CNO Medicare Supplement NAP +53% and GL Health premium +12.7% confirm the disenrollment pool is real and broad. Single-name analysts don't aggregate flow across the cohort.

89% idiosyncratic variance. Trailing 250-day regression vs SPY/QQQ/XLV: HUM idio 89%, XLV variance contribution 7.6%. UNH and ELV are 21-24% sector. HUM moves on HUM-specific factors. The sector beat is being priced; the structural scale advantage compounding into BY2027 STARS recovery is not.

RADV 5th Circuit binary unpriced. HUM is the named plaintiff. Affirmance preserves the FFS Adjuster and blocks extrapolated audits across the MA complex; reversal forces a $1.5-2B reserve. Resolution 12-24 months out.

Risks (ranked)

1. 5th Circuit reverses RADV vacatur — high probability (estimated 40-50%), $1.5-2B reserve plus likely multiple compression. Structural thesis-breaker independent of operations.
2. CenterWell J-curve drag persists beyond v28 phase-in — Q1 OCR +340 bps, integration costs continuing.
3. AEP 2026 attrition — the +1.18M cohort needs to retain through next enrollment.
4. BY2027 Star Ratings disappoint — Oct 2026 release; bid assumptions already filed.
5. DOJ False Claims Act broker-compensation case — May 2025 complaint, no resolution timeline.

Catalysts

• Jul 29, 2026 — Q2 2026 earnings. Three falsifiable predictions resolve same day.
• Oct 2026 — BY2027 Star Ratings released.
• Oct 15 - Dec 7, 2026 — AEP 2026 enrollment.
• Late 2026 - late 2027 — 5th Circuit ruling in Humana v Kennedy.
• Feb 2027 — FY 2026 10-K.

What would change our mind

• Q2 2026 EPS materially below $5.10 estimate — full-year run-rate breaks below thesis.
• UNH or ELV reverse course in 2026 bid filings — absorption was AEP 2025-specific.
• 5th Circuit briefing reveals near-term adverse ruling.
• BY2027 weighted star ratings below 4.0.
• Resumption of insider selling that supersedes the December 2025 - February 2026 pattern.

The trough entry at $185 carried α/σ_idio of roughly 0.75 — a fat pitch. From $236, the same math yields about 0.15 — a phased-entry sizing call, not a full-position one. The asymmetric setup is gone; the thesis is not.

Evidence